Welcome to our dedicated page for DiaMedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on DiaMedica Therapeutics stock.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with significant unmet clinical needs, especially in the fields of neurological and kidney diseases. The company's primary product candidate, DM199, is a recombinant form of human tissue kallikrein-1, aimed at addressing conditions such as chronic kidney disease and acute ischemic stroke.
By leveraging cutting-edge research and development, DiaMedica aims to provide patients with effective therapeutic options where no current therapies exist. The company has made substantial progress in clinical trials, showcasing promising results that have caught the attention of both the medical community and investors.
Recent achievements include positive data from Phase II clinical trials, partnerships with leading healthcare institutions, and securing significant funding to advance its research and development efforts. These milestones indicate strong potential for future growth and a positive impact on patient care.
Financially, DiaMedica is poised for growth, backed by a robust pipeline and strategic collaborations. As the company forges ahead, it continues to draw interest from investors looking for opportunities in the biopharmaceutical sector.
For the latest updates on DiaMedica Therapeutics Inc., including recent news and developments, visit the company's website.
DiaMedica Therapeutics, a clinical-stage biopharmaceutical company, has closed an $11.8 million private placement. The company sold approximately 4.7 million common shares at $2.50 per share, a 10% premium over the previous closing price. Net proceeds were about $11.7 million, increasing the company's cash and investments to $58.2 million on a pro forma basis. Major investors include Thomas von Koch and Trill AB, each acquiring 1.2 million shares at $2.50 per share, raising their holdings to 12.9% and 12.2% of the company, respectively.
DiaMedica Therapeutics (Nasdaq: DMAC) announced a private placement of common shares to accredited investors, aiming to raise $11.8 million. The company will issue 4,720,000 shares at $2.50 each, with the transaction expected to close around June 28, 2024. The proceeds will fund ongoing clinical trials for DM199, including Phase 2/3 ReMEDy2 for acute ischemic stroke and expansion into preeclampsia. This financing will extend DiaMedica's cash runway into Q3 2026. The common shares offered are not registered under the Securities Act of 1933 and will require a registration statement for resale. Related parties have committed $6.0 million, making this a 'related party transaction' under Canadian regulations, but exempt from certain requirements due to the transaction's size relative to the company's market capitalization.
DiaMedica Therapeutics announced the expansion of its DM199 (rinvecalinase alfa) clinical development program to include preeclampsia, a severe pregnancy-associated disorder. The Phase 2 trial will begin in Q4 2024, with key results expected in H1 2025. The trial aims to enroll up to 120 participants at an estimated cost of $1.5 million. DM199 has shown potential in lowering blood pressure and improving endothelial health, critical for pregnant women. The study will evaluate up to 90 women with preeclampsia and 30 with fetal growth restriction. Initial findings indicate DM199 does not cross the placental barrier, suggesting a significant safety advantage.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) provided a business update and financial results for Q1 2024, reporting $46.5 million cash with runway to 2026. They dosed the first patient in the ReMEDy2 Stroke Trial, with a projected enrollment completion by Q1 2025. The company expanded its clinical operations team to support global expansion. Financially, R&D expenses increased, but G&A expenses remained steady. DiaMedica held a conference call to discuss these updates and financial results.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its first quarter 2024 financial results on May 8th, followed by a business update and live conference call on May 9th. The company focuses on developing recombinant KLK1 (DM199) for acute ischemic stroke treatment.
FAQ
What is the current stock price of DiaMedica Therapeutics (DMAC)?
What is the market cap of DiaMedica Therapeutics (DMAC)?
What does DiaMedica Therapeutics Inc. do?
What is DM199?
What are the recent achievements of DiaMedica Therapeutics?
Which diseases are DiaMedica Therapeutics targeting?
How can I get updates on DiaMedica Therapeutics?
Is DiaMedica Therapeutics a publicly traded company?
What stage of development is DiaMedica Therapeutics currently in?
What makes DiaMedica Therapeutics unique?
Who can benefit from DiaMedica's products?
Has DiaMedica secured any partnerships?
